{"schema_version":"secwatch.filing_event.v1","accession":"0000711404-22-000023","form_type":"8-K","ticker":"COO","cik":"0000711404","company_name":"COOPER COMPANIES, INC.","filed_at":"2022-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.431925+00:00","generated_at":"2026-06-25T05:15:47.852848+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CooperCompanies Q2 rev up 15% to $829.8M; GAAP EPS $2.55, adj EPS $3.24","bullets":["CooperVision revenue $553.8M (+6% reported, +12% organic); toric and multifocal sales strong.","CooperSurgical revenue $276.0M (+40% reported, +6% organic); fertility segment organic growth 15%.","FY2022 guidance: revenue $3.28-3.312B, non-GAAP diluted EPS $13.09-13.29, reflecting FX headwinds.","Exited contact lens solutions business in April; closed SightGlass JV with EssilorLuxottica in March."],"urls":{"canonical":"https://secwatch.observer/filing/0000711404-22-000023","json":"https://secwatch.observer/filing/0000711404-22-000023.json","markdown":"https://secwatch.observer/filing/0000711404-22-000023.md","text":"https://secwatch.observer/filing/0000711404-22-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/711404/000071140422000023/0000711404-22-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/711404/000071140422000023/coo-20220602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:15:47.852848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}